-
Mashup Score: 2Reports From the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer - The ASCO Post - 2 year(s) ago
The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer was held recently in Phoenix, Arizona. On this episode, we’ll hear from two researchers who presented data at the meeting on ovarian and cervical cancers. …
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Pedro Ramirez on Hysterectomy for Early Cervical Cancer New Findings on Open vs Minimally Invasive Surgery - The ASCO Post - 2 year(s) ago
The ASCO Post Staff Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses findings from the SORAYA study on the efficacy and safety of mirvetuximab soravtansine in patients who have platinum-resistant ovarian cancer with high folate…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery https://t.co/wOFe23PWHy #gyncsm #oncology #cancer #SGO22 @SGO_org https://t.co/wG7zBLm8wK
-
-
Mashup Score: 0Ursula Matulonis on Ovarian Cancer New Data on Mirvetuximab Soravtansine - The ASCO Post - 2 year(s) ago
Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery Pedro T. Ramirez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final analysis of the LACC trial (Laparoscopic Approach to Cervical Cancer), which showed that women with early cervical cancer who need a…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine https://t.co/RKVoqySPAI #SGO22 #gyncsm #oncology #cancer @DrMatulonis @DanaFarber @SGO_org https://t.co/TxJ3uI46ob
-
-
Mashup Score: 0Niraparib Maintenance Therapy Improves Progression-Free Survival in Advanced Ovarian Cancer - The ASCO Post - 2 year(s) ago
A larger population of patients with newly diagnosed advanced ovarian cancer may be able to benefit from niraparib maintenance therapy, with an improved safety profile, according to phase III data presented at the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.1 Results of the phase III PRIME…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PRIME Trial: Niraparib Maintenance Therapy Improves Progression-Free Survival in Advanced Ovarian Cancer https://t.co/QoIc6iQa7d #gyncsm #SGO22
-
-
Mashup Score: 0Intraperitoneal Carboplatin Plus Paclitaxel vs Intravenous Chemotherapy in Ovarian Cancer - The ASCO Post - 2 year(s) ago
When compared with intravenous (IV) chemotherapy, the use of intraperitoneal (IP) carboplatin with dose-dense weekly paclitaxel improved progression-free survival in patients with ovarian, fallopian tube, or primary peritoneal carcinoma, according to data presented at the 2022 Society of Gynecologic Oncology (SGO) Annual…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Intraperitoneal Carboplatin Plus Paclitaxel vs Intravenous Chemotherapy in Ovarian Cancer https://t.co/3NEupbo2N5 #SGO22 #gyncsm #oncology #cancer
-
-
Mashup Score: 0Nemvaleukin Alfa/Pembrolizumab Combo Shows Promising Activity in Platinum-Resistant Ovarian Cancer - 2 year(s) ago
The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy. @karmanoscancer #SGO22 #ovcasm #gyncsm https://t.co/8d4pjfGCck
-
-
Mashup Score: 1
Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer. @HUST_China #SGO22 #ovca #gyncsm https://t.co/M30J0RIV1J https://t.co/TSck75a0mn
-
-
Mashup Score: 1Nemvaleukin Alfa/Pembrolizumab Combo Shows Promising Activity in Platinum-Resistant Ovarian Cancer - 2 year(s) ago
The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to data from the phase 1/2 ARTISTRY-1 trial, nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in pts w/ pretreated ovarian cancer who are resistant to platinum-based chemotherapy. @karmanoscancer #SGO22 #gyncsm #gyncsm https://t.co/Xf7mCBVnfI https://t.co/DxWdOuug5f
-
-
Mashup Score: 0Intravenous Chemo/Bevacizumab Shows Comparable Survival Outcomes Vs Intraperitoneal Regimen in Advanced Ovarian Cancer - 2 year(s) ago
Intravenous chemotherapy plus bevacizumab did not demonstrate differences in progression-free and overall survival compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Intravenous chemotherapy + bevacizumab did not demonstrate differences in PFS & OS compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease. @OUHealth #SGO22 #ovcasm #gyncsm https://t.co/UzgHXc6dQz
-
-
Mashup Score: 0
Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer. @HUST_China #SGO22 #ovca #gyncsm https://t.co/htqTJOj0ZM
-
Reports From the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer https://t.co/iw25rgUJXZ #SGO22 #gyncsm #oncology #cancer